Aspire Biopharma Holdings, Inc.是一家专注于开发和营销创新的舌下给药机制的公司，针对已知药物和补充剂，已发布其第三季度的 10-Q 报告。该报告详细概述了公司的财务表现和业务运营，反映了其早期阶段的状态以及不断扩展市场存在的努力。
财务亮点
<ul>
<li>净收入：$1,941 - 公司在此期间报告的收入极少，表明处于早期运营阶段。</li>
<li>毛利润：$884 - 反映了产品销售的初始阶段，盈利能力有限。</li>
<li>运营损失：$(17,501,867) - 公司经历了显著的运营损失，主要由于高额的管理和行政费用，包括基于股票的补偿。</li>
<li>净亏损：$(19,773,114) - 大额净亏损归因于高额的运营费用和利息费用。</li>
<li>普通股基本和稀释每股净亏损：$(0.43) - 反映了净亏损对股东的影响。</li>
</ul>
业务亮点
<ul>
<li>收入细分：公司报告了来自营养保健产品的收入，销售主要发生在美国，少部分在加拿大。这表明其产品分销主要集中在北美市场。</li>
<li>地域表现：大部分销售集中在美国，占总收入的$1,901，加拿大贡献$40。这表明公司在国内市场的强大存在，国际市场的覆盖有限。</li>
<li>新产品发布：Aspire Biopharma Holdings, Inc.专注于开发和营销颠覆性技术，针对新型舌下给药机制，最初目标是已知药物和补充剂，如阿司匹林和咖啡因产品。这表明公司在制药和补充剂行业内持续创新的努力。</li>
<li>未来展望：公司计划继续专注于扩大销售和营销努力，以及研究和开发活动。然而，公司承认需要额外融资来支持这些计划，这可能涉及通过股权发行筹集资金。</li>
</ul>
SEC 文件：Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q -2025 年 11 月 14 日

ASBP

Aspire Biopharma Holdings, Inc. 发布了其第三季度的 10-Q 报告，报告显示收入仅为 1,941 美元，净亏损高达 19,773,114 美元。该公司专注于药物和补充剂的舌下给药机制，绝大多数销售在美国。未来计划包括扩大销售、市场营销和研发，这需要额外的融资

Aspire Biopharma Holdings, Inc., a company focused on developing and marketing innovative sublingual delivery mechanisms for known drugs and supplements, has released its Form 10-Q report for the third quarter. The report provides a detailed overview of the company's financial performance and business operations, reflecting its early-stage status and ongoing efforts to expand its market presence.
<div class="lb-trans">Aspire Biopharma Holdings, Inc.是一家专注于开发和营销创新的舌下给药机制的公司，针对已知药物和补充剂，已发布其第三季度的 10-Q 报告。该报告详细概述了公司的财务表现和业务运营，反映了其早期阶段的状态以及不断扩展市场存在的努力。
</div>Financial Highlights
<div class="lb-trans">财务亮点
</div><ul>
<li>Net Revenue: $1,941 - The company reported minimal revenue for the period, indicating early-stage operations.</li>
<li>Gross Profit: $884 - Reflects the initial stages of product sales with limited profitability.</li>
<li>Loss from Operations: $(17,501,867) - The company experienced significant operating losses, primarily due to high general and administrative expenses, including stock-based compensation.</li>
<li>Net Loss: $(19,773,114) - The substantial net loss is attributed to high operating expenses and interest expenses.</li>
<li>Basic and diluted net loss per share of Common Stock: $(0.43) - Reflects the impact of the net loss on shareholders.</li>
</ul>
<div class="lb-trans"><ul>
<li>净收入：$1,941 - 公司在此期间报告的收入极少，表明处于早期运营阶段。</li>
<li>毛利润：$884 - 反映了产品销售的初始阶段，盈利能力有限。</li>
<li>运营损失：$(17,501,867) - 公司经历了显著的运营损失，主要由于高额的管理和行政费用，包括基于股票的补偿。</li>
<li>净亏损：$(19,773,114) - 大额净亏损归因于高额的运营费用和利息费用。</li>
<li>普通股基本和稀释每股净亏损：$(0.43) - 反映了净亏损对股东的影响。</li>
</ul>
</div>Business Highlights
<div class="lb-trans">业务亮点
</div><ul>
<li>Revenue Segments: The company reported revenue from nutraceutical products, with sales primarily occurring in the USA and a small portion in Canada. This indicates a focus on the North American market for its product distribution.</li>
<li>Geographical Performance: The majority of sales were concentrated in the USA, accounting for $1,901 of the total revenue, with Canada contributing $40. This suggests a strong domestic market presence with limited international reach.</li>
<li>New Product Launches: Aspire Biopharma Holdings, Inc. is focused on developing and marketing disruptive technology for novel sublingual delivery mechanisms, initially targeting known drugs and supplements such as aspirin and caffeine products. This indicates ongoing efforts to innovate within the pharmaceutical and supplements industry.</li>
<li>Future Outlook: The company plans to continue its focus on expanding sales and marketing efforts, as well as research and development activities. However, it acknowledges the need for additional financing to support these initiatives, which may involve raising capital through equity issuances.</li>
</ul>
<div class="lb-trans"><ul>
<li>收入细分：公司报告了来自营养保健产品的收入，销售主要发生在美国，少部分在加拿大。这表明其产品分销主要集中在北美市场。</li>
<li>地域表现：大部分销售集中在美国，占总收入的$1,901，加拿大贡献$40。这表明公司在国内市场的强大存在，国际市场的覆盖有限。</li>
<li>新产品发布：Aspire Biopharma Holdings, Inc.专注于开发和营销颠覆性技术，针对新型舌下给药机制，最初目标是已知药物和补充剂，如阿司匹林和咖啡因产品。这表明公司在制药和补充剂行业内持续创新的努力。</li>
<li>未来展望：公司计划继续专注于扩大销售和营销努力，以及研究和开发活动。然而，公司承认需要额外融资来支持这些计划，这可能涉及通过股权发行筹集资金。</li>
</ul>
</div>SEC Filing: Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q - Nov. 14, 2025
<div class="lb-trans">SEC 文件：Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q -2025 年 11 月 14 日
</div>

Aspire Biopharma Holdings, Inc. 的 SEC 10-Q 报告